Liontrust Investment Partners LLP Makes New Investment in Becton, Dickinson and Company $BDX

Key Points

• Liontrust Investment Partners LLP has acquired a new position in Becton, Dickinson and Company, purchasing 497,549 shares valued at approximately $113.97 million, which makes BDX the 20th largest holding in their portfolio.
• Becton, Dickinson reported a 10.4% year-over-year revenue increase with a quarterly revenue of $5.51 billion, surpassing analyst expectations.
• The company announced a quarterly dividend of $1.04 per share, which reflects an annualized yield of 2.1% and a payout ratio of 74.82%.

Liontrust Investment Partners LLP acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 497,549 shares of the medical instruments supplier's stock, valued at approximately $113,969,000. Becton, Dickinson and Company makes up approximately 1.8% of Liontrust Investment Partners LLP's investment portfolio, making the stock its 20th biggest position. Liontrust Investment Partners LLP owned approximately 0.17% of Becton, Dickinson and Company as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Brighton Jones LLC lifted its position in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after acquiring an additional 877 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of Becton, Dickinson and Company by 50.6% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier's stock worth $18,808,000 after purchasing an additional 27,581 shares in the last quarter. Foster Victor Wealth Advisors LLC purchased a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at about $6,406,000. GAMMA Investing LLC boosted its position in shares of Becton, Dickinson and Company by 29.9% in the 1st quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier's stock valued at $744,000 after purchasing an additional 748 shares during the period. Finally, Ritholtz Wealth Management acquired a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at about $224,000. Institutional investors and hedge funds own 86.97% of the company's stock.

Becton, Dickinson and Company Stock Performance

NYSE:BDX traded up $1.2180 during mid-day trading on Wednesday, reaching $199.2480. The stock had a trading volume of 2,493,478 shares, compared to its average volume of 2,751,564. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The business has a 50 day simple moving average of $179.66 and a 200 day simple moving average of $196.25. The firm has a market capitalization of $57.11 billion, a price-to-earnings ratio of 35.84, a PEG ratio of 1.48 and a beta of 0.20. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping the consensus estimate of $3.40 by $0.28. The company had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business's revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the firm earned $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be paid a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 74.82%.

Analyst Ratings Changes

A number of brokerages have weighed in on BDX. Citigroup cut Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and reduced their price objective for the company from $217.00 to $185.00 in a research note on Thursday, May 22nd. William Blair cut shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Thursday, May 1st. Bank of America cut shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 price target for the company. in a research note on Thursday, May 1st. Piper Sandler reissued a "neutral" rating and set a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Finally, Morgan Stanley upped their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Four equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company presently has an average rating of "Hold" and an average target price of $211.44.

Insider Buying and Selling

In other news, EVP Michael David Garrison sold 1,185 shares of the business's stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares of the company's stock, valued at $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP David Shan sold 1,166 shares of the company's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the transaction, the executive vice president owned 4,575 shares in the company, valued at approximately $783,194.25. This trade represents a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,214 shares of company stock worth $579,206 in the last ninety days. Insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.